# Keysight Technologies, Inc.: financial statements, quarterly

KEYS · NYSE · CIK 1601046 · [Technology](/sectors/technology.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/keys.md) · [Financials](/companies/keys/financials.md) · [Filings](/companies/keys/filings.md) · [Insiders](/companies/keys/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/keys/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,311 d](/filings/0001601046-25-000127.md) | [1,259](/filings/0001601046-25-000009.md) | [1,216](/filings/0001601046-25-000073.md) | [1,217](/filings/0001601046-25-000091.md) | [1,287 d](/filings/0001601046-25-000127.md) | [1,298](/filings/0001601046-26-000008.md) | [1,306](/filings/0001601046-26-000024.md) | [1,352](/filings/0001601046-26-000036.md) | [1,419 d](/filings/0001601046-25-000127.md) | [1,600](/filings/0001601046-26-000008.md) | [1,717](/filings/0001601046-26-000024.md) | [1,846](/filings/0001601046-26-000036.md) |
| Cost of revenue | $m | [467 d](/filings/0001601046-25-000127.md) | [446](/filings/0001601046-25-000009.md) | [453](/filings/0001601046-25-000073.md) | [462](/filings/0001601046-25-000091.md) | [485 d](/filings/0001601046-25-000127.md) | [478](/filings/0001601046-26-000008.md) | [492](/filings/0001601046-26-000024.md) | [518](/filings/0001601046-26-000036.md) | [550 d](/filings/0001601046-25-000127.md) | [605](/filings/0001601046-26-000008.md) | [539](/filings/0001601046-26-000024.md) | [630](/filings/0001601046-26-000036.md) |
| Research and development | $m | [218 d](/filings/0001601046-25-000127.md) | [232](/filings/0001601046-25-000009.md) | [228](/filings/0001601046-25-000073.md) | [226](/filings/0001601046-25-000091.md) | [233 d](/filings/0001601046-25-000127.md) | [249](/filings/0001601046-26-000008.md) | [250](/filings/0001601046-26-000024.md) | [250](/filings/0001601046-26-000036.md) | [258 d](/filings/0001601046-25-000127.md) | [303](/filings/0001601046-26-000008.md) | [320](/filings/0001601046-26-000024.md) | [312](/filings/0001601046-26-000036.md) |
| Selling, general and administrative | $m | [313 d](/filings/0001601046-25-000127.md) | [362](/filings/0001601046-25-000009.md) | [361](/filings/0001601046-25-000073.md) | [329](/filings/0001601046-25-000091.md) | [343 d](/filings/0001601046-25-000127.md) | [361](/filings/0001601046-26-000008.md) | [360](/filings/0001601046-26-000024.md) | [354](/filings/0001601046-26-000036.md) | [399 d](/filings/0001601046-25-000127.md) | [447](/filings/0001601046-26-000008.md) | [456](/filings/0001601046-26-000024.md) | [446](/filings/0001601046-26-000036.md) |
| Operating income | $m | [317 d](/filings/0001601046-25-000127.md) | [221](/filings/0001601046-25-000009.md) | [177](/filings/0001601046-25-000073.md) | [205](/filings/0001601046-25-000091.md) | [230 d](/filings/0001601046-25-000127.md) | [218](/filings/0001601046-26-000008.md) | [207](/filings/0001601046-26-000024.md) | [234](/filings/0001601046-26-000036.md) | [217 d](/filings/0001601046-25-000127.md) | [248](/filings/0001601046-26-000008.md) | [407](/filings/0001601046-26-000024.md) | [461](/filings/0001601046-26-000036.md) |
| Interest expense | $m | [20.0 d](/filings/0001601046-25-000127.md) | [20.0](/filings/0001601046-24-000005.md) | [20.0](/filings/0001601046-25-000073.md) | [21.0](/filings/0001601046-25-000091.md) | [23.0 d](/filings/0001601046-25-000127.md) | [20.0](/filings/0001601046-26-000008.md) | [20.0](/filings/0001601046-26-000024.md) | [28.0](/filings/0001601046-26-000036.md) | [28.0 d](/filings/0001601046-25-000127.md) | [29.0](/filings/0001601046-26-000008.md) | [25.0](/filings/0001601046-26-000024.md) | [26.0](/filings/0001601046-26-000036.md) |
| Income tax | $m | [50.0 d](/filings/0001601046-25-000127.md) | [57.0](/filings/0001601046-25-000009.md) | [49.0](/filings/0001601046-25-000073.md) | [(176)](/filings/0001601046-25-000091.md) | [321 d](/filings/0001601046-25-000127.md) | [30.0](/filings/0001601046-26-000008.md) | [63.0](/filings/0001601046-26-000024.md) | [50.0](/filings/0001601046-26-000036.md) | [70.0 d](/filings/0001601046-25-000127.md) | [(83.0)](/filings/0001601046-26-000008.md) | [69.0](/filings/0001601046-26-000024.md) | [80.0](/filings/0001601046-26-000036.md) |
| Net income | $m | [226 d](/filings/0001601046-25-000127.md) | [172](/filings/0001601046-25-000009.md) | [126](/filings/0001601046-25-000073.md) | [389](/filings/0001601046-25-000091.md) | [(73.0) d](/filings/0001601046-25-000127.md) | [169](/filings/0001601046-26-000008.md) | [257](/filings/0001601046-26-000024.md) | [191](/filings/0001601046-26-000036.md) | [233 d](/filings/0001601046-25-000127.md) | [281](/filings/0001601046-26-000008.md) | [349](/filings/0001601046-26-000024.md) | [397](/filings/0001601046-26-000036.md) |
| Diluted EPS | $ per share | not reported | [0.98](/filings/0001601046-25-000009.md) | [0.72](/filings/0001601046-25-000073.md) | [2.22](/filings/0001601046-25-000091.md) | not reported | [0.97](/filings/0001601046-26-000008.md) | [1.49](/filings/0001601046-26-000024.md) | [1.10](/filings/0001601046-26-000036.md) | not reported | [1.63](/filings/0001601046-26-000008.md) | [2.02](/filings/0001601046-26-000024.md) | [2.30](/filings/0001601046-26-000036.md) |
| Basic EPS | $ per share | not reported | [0.98](/filings/0001601046-25-000009.md) | [0.73](/filings/0001601046-25-000073.md) | [2.23](/filings/0001601046-25-000091.md) | not reported | [0.97](/filings/0001601046-26-000008.md) | [1.49](/filings/0001601046-26-000024.md) | [1.11](/filings/0001601046-26-000036.md) | not reported | [1.64](/filings/0001601046-26-000008.md) | [2.04](/filings/0001601046-26-000024.md) | [2.33](/filings/0001601046-26-000036.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.5](/filings/0001601046-24-000159.md) | [1.7](/filings/0001601046-24-000005.md) | [1.7](/filings/0001601046-24-000043.md) | [1.6](/filings/0001601046-24-000061.md) | [1.8](/filings/0001601046-25-000127.md) | [2.1](/filings/0001601046-25-000009.md) | [3.1](/filings/0001601046-25-000073.md) | [2.6](/filings/0001601046-25-000091.md) | [1.9](/filings/0001601046-26-000036.md) | [2.2](/filings/0001601046-26-000008.md) | [2.4](/filings/0001601046-26-000024.md) | [2.6](/filings/0001601046-26-000036.md) |
| Current assets | $bn | [4.8](/filings/0001601046-24-000159.md) | [4.1](/filings/0001601046-24-000005.md) | [4.0](/filings/0001601046-24-000043.md) | [4.0](/filings/0001601046-24-000061.md) | [4.3](/filings/0001601046-25-000127.md) | [4.5](/filings/0001601046-25-000009.md) | [5.5](/filings/0001601046-25-000073.md) | [5.6](/filings/0001601046-25-000091.md) | [4.3](/filings/0001601046-26-000036.md) | [4.7](/filings/0001601046-26-000008.md) | [5.0](/filings/0001601046-26-000024.md) | [5.3](/filings/0001601046-26-000036.md) |
| Total assets | $bn | [8.7](/filings/0001601046-24-000159.md) | [9.1](/filings/0001601046-24-000005.md) | [9.0](/filings/0001601046-24-000043.md) | [9.3](/filings/0001601046-24-000061.md) | [9.3](/filings/0001601046-25-000127.md) | [9.4](/filings/0001601046-25-000009.md) | [10.5](/filings/0001601046-25-000073.md) | [10.7](/filings/0001601046-25-000091.md) | [11.3](/filings/0001601046-26-000036.md) | [11.5](/filings/0001601046-26-000008.md) | [11.7](/filings/0001601046-26-000024.md) | [11.9](/filings/0001601046-26-000036.md) |
| Current liabilities | $bn | [2.0](/filings/0001601046-24-000159.md) | [2.1](/filings/0001601046-24-000005.md) | [2.0](/filings/0001601046-24-000043.md) | [1.9](/filings/0001601046-24-000061.md) | [1.4](/filings/0001601046-25-000127.md) | [1.5](/filings/0001601046-25-000009.md) | [1.6](/filings/0001601046-25-000073.md) | [1.6](/filings/0001601046-25-000091.md) | [1.9](/filings/0001601046-26-000036.md) | [1.8](/filings/0001601046-26-000008.md) | [2.6](/filings/0001601046-26-000024.md) | [2.6](/filings/0001601046-26-000036.md) |
| Total liabilities | $bn | [4.0](/filings/0001601046-24-000159.md) | [4.2](/filings/0001601046-24-000005.md) | [4.1](/filings/0001601046-24-000043.md) | [4.1](/filings/0001601046-24-000061.md) | [4.2](/filings/0001601046-25-000127.md) | [4.2](/filings/0001601046-25-000009.md) | [5.1](/filings/0001601046-25-000073.md) | [5.0](/filings/0001601046-25-000091.md) | [5.4](/filings/0001601046-26-000036.md) | [5.3](/filings/0001601046-26-000008.md) | [5.4](/filings/0001601046-26-000024.md) | [5.4](/filings/0001601046-26-000036.md) |
| Long-term debt | $bn | [1.2](/filings/0001601046-24-000159.md) | [1.2](/filings/0001601046-24-000005.md) | [1.2](/filings/0001601046-24-000043.md) | [1.2](/filings/0001601046-24-000061.md) | [1.8](/filings/0001601046-25-000127.md) | [1.8](/filings/0001601046-25-000009.md) | [2.5](/filings/0001601046-25-000073.md) | [2.5](/filings/0001601046-25-000091.md) | [2.5](/filings/0001601046-26-000036.md) | [2.5](/filings/0001601046-26-000008.md) | [1.8](/filings/0001601046-26-000024.md) | [1.8](/filings/0001601046-26-000036.md) |
| Current portion of debt | $bn | [0.6](/filings/0001601046-24-000159.md) | [0.6](/filings/0001601046-24-000005.md) | [0.6](/filings/0001601046-24-000043.md) | [0.6](/filings/0001601046-24-000061.md) | [0.0](/filings/0001601046-24-000159.md) | not reported | not reported | not reported | [0.0](/filings/0001601046-26-000036.md) | not reported | [0.7](/filings/0001601046-26-000024.md) | [0.7](/filings/0001601046-26-000036.md) |
| Shareholders' equity | $bn | [4.7](/filings/0001601046-24-000159.md) | [4.8](/filings/0001601046-24-000005.md) | [4.9](/filings/0001601046-24-000043.md) | [5.2](/filings/0001601046-24-000061.md) | [5.1](/filings/0001601046-25-000127.md) | [5.2](/filings/0001601046-25-000009.md) | [5.5](/filings/0001601046-25-000073.md) | [5.7](/filings/0001601046-25-000091.md) | [5.9](/filings/0001601046-26-000036.md) | [6.2](/filings/0001601046-26-000008.md) | [6.3](/filings/0001601046-26-000024.md) | [6.6](/filings/0001601046-26-000036.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [378 d](/filings/0001601046-25-000127.md) | [328](/filings/0001601046-25-000009.md) | [110 d](/filings/0001601046-25-000073.md) | [255 d](/filings/0001601046-25-000091.md) | [359 d](/filings/0001601046-25-000127.md) | [378](/filings/0001601046-26-000008.md) | [484 d](/filings/0001601046-26-000024.md) | [322 d](/filings/0001601046-26-000036.md) | [225 d](/filings/0001601046-25-000127.md) | [441](/filings/0001601046-26-000008.md) | [501 d](/filings/0001601046-26-000024.md) | [437 d](/filings/0001601046-26-000036.md) |
| Capital expenditure | $m | [39.0 d](/filings/0001601046-25-000127.md) | [47.0](/filings/0001601046-25-000009.md) | [36.0 d](/filings/0001601046-25-000073.md) | [33.0 d](/filings/0001601046-25-000091.md) | [38.0 d](/filings/0001601046-25-000127.md) | [32.0](/filings/0001601046-26-000008.md) | [27.0 d](/filings/0001601046-26-000024.md) | [31.0 d](/filings/0001601046-26-000036.md) | [38.0 d](/filings/0001601046-25-000127.md) | [34.0](/filings/0001601046-26-000008.md) | [29.0 d](/filings/0001601046-26-000024.md) | [34.0 d](/filings/0001601046-26-000036.md) |
| Share repurchases | $m | [426 d](/filings/0001601046-25-000127.md) | [93.0](/filings/0001601046-25-000009.md) | [46.0 d](/filings/0001601046-25-000073.md) | [150 d](/filings/0001601046-25-000091.md) | [150 d](/filings/0001601046-25-000127.md) | [75.0](/filings/0001601046-26-000008.md) | [150 d](/filings/0001601046-26-000024.md) | [50.0 d](/filings/0001601046-26-000036.md) | [100 d](/filings/0001601046-25-000127.md) | [87.0](/filings/0001601046-26-000008.md) | [220 d](/filings/0001601046-26-000024.md) | [210 d](/filings/0001601046-26-000036.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [180](/filings/0001601046-24-000005.md) | [179](/filings/0001601046-24-000043.md) | [179](/filings/0001601046-24-000061.md) | [176](/filings/0001601046-25-000009.md) | [175](/filings/0001601046-25-000073.md) | [175](/filings/0001601046-25-000091.md) | [174](/filings/0001601046-26-000008.md) | [173](/filings/0001601046-26-000024.md) | [173](/filings/0001601046-26-000036.md) | [173](/filings/0001601046-26-000008.md) | [173](/filings/0001601046-26-000024.md) | [173](/filings/0001601046-26-000036.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 170,244,745 at 2026-08-27, from the cover of the [10-Q filed 2026-09-02](/filings/0001601046-26-000036.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.